Jubilant Pharmova Ltd.
Price
Daily candles · NSEPrice history isn’t available for this scrip.
What the numbers say
- Low return on equity: 3-year ROE 7.2%.
- Comfortable leverage: debt-to-equity of 0.46.
- Sales growth muted at 9.6% over 3 years.
- Profits convert to cash well (CFO/OP 0.93).
- Trades above its industry P/E (37.1 vs 25.9).
Generated automatically from reported financials. These are observations, not a recommendation to buy or sell.
- Abakkus Asset Managers buys 0.69% stake in Jubilant Pharmova
Abakkus Four2Eight Opportunities Fund has bought 11 lakh shares of the company for around Rs 100.65 crore
- Jubilant Pharmova gets nod to raise up to Rs 800 crore via NCDs
The Board of Directors of the Company, at its meeting held on October 12, 2026, has, inter alia, considered and approved the same
- Jubilant Pharmova's arm to invest 94.5 million Canadian Dollar to double RUBY-FILL capacity
The Government of Canada will provide a financial support of 23.8 million Canadian Dollar to this project
- Jubilant Pharmova gets USFDA's approval for new Isolator based fill and finish line at Spokane Facility
Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is a subsidiary of Jubilant Pharma, Singapore, a wholly owned subsidiary of the company
- USFDA concludes inspection at Jubilant Pharmova’s arm’s facility in U.S.A
JHS will respond to the inspection observations within 15 business days
Company announcements as filed with the exchanges. Reproduced for information — not a view or a recommendation.
| Profit & Loss · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Net Sales | 8,280 | 7,235 | 6,703 | 6,282 | 6,130 |
| Other income | 66 | 57 | 69 | 38 | 11 |
| Total Income | 8,346 | 7,291 | 6,772 | 6,320 | 6,141 |
| Expenditure | 7,020 | 6,061 | 5,802 | 5,506 | 4,974 |
| Operating Profit | 1,326 | 1,231 | 970 | 815 | 1,168 |
| Interest | 212 | 240 | 272 | 188 | 145 |
| Depreciation | 440 | 369 | 382 | 554 | 382 |
| Profit before tax | 614 | 981 | 171 | 28 | 630 |
| Tax | 217 | 144 | 98 | 93 | 217 |
| Net Profit | 398 | 836 | 73 | -65 | 413 |
| EPS (₹) | 25.15 | 52.99 | 4.87 | -3.83 | 26.00 |
| Net margin % | 4.8 | 11.6 | 1.1 | -1.0 | 6.7 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Balance Sheet · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Equity capital | 16 | 16 | 16 | 16 | 16 |
| Reserves | 7,058 | 6,224 | 5,404 | 5,377 | 5,299 |
| Net worth | 7,074 | 6,240 | 5,419 | 5,393 | 5,315 |
| Total sources | 12,733 | 10,420 | 9,449 | 9,078 | 8,096 |
| Net block | 6,966 | 5,176 | 5,091 | 5,183 | 4,871 |
| Capital work in progress | 4,040 | 3,630 | 2,103 | 1,562 | 1,090 |
| Investments | 150 | 116 | 245 | 422 | 360 |
| Inventory | 1,232 | 1,129 | 1,290 | 1,381 | 1,255 |
| Debtors | 1,070 | 892 | 916 | 961 | 928 |
| Cash & bank | 1,268 | 1,089 | 957 | 1,014 | 984 |
| Book value (₹) | 447.70 | 394.94 | 343.00 | 339.19 | 333.91 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Cash Flow · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| From operations | 1,227 | 1,072 | 971 | 661 | 838 |
| From investing | -1,260 | 488 | -608 | -544 | -380 |
| From financing | 95 | -1,453 | -433 | -157 | -33 |
| Net change in cash | 62 | 107 | -69 | -40 | 425 |
| Free cash flow | -33 | 1,560 | 363 | 116 | 457 |
| Closing cash | 1,267 | 1,088 | 956 | 1,014 | 984 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Ratios | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| ROCE % | 8.7 | 13.9 | 5.0 | 2.5 | 10.0 |
| ROE % | 6.0 | 14.3 | 1.3 | -1.2 | 8.2 |
| PAT margin % | 4.5 | 10.9 | 1.1 | -1.0 | 6.7 |
| EBIT margin % | 9.4 | 16.0 | 6.6 | 3.4 | 12.7 |
| Debt / equity | 0.46 | 0.39 | 0.63 | 0.63 | 0.55 |
| Current ratio | 1.62 | 1.62 | 1.92 | 2.12 | 2.20 |
| Interest cover | 3.90 | 5.08 | 1.63 | 1.15 | 5.33 |
| Sales growth % | 14.4 | 7.9 | 6.7 | 2.5 | 0.5 |
| Dividend per share (₹) | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Payout % | 19.8 | 9.4 | 102.5 | -130.3 | 19.2 |
Consolidated figures, as filed with the exchanges. Newest year first.
Frequently asked
Jubilant Pharmova Ltd. (JUBLPHARMA) last traded at ₹932.20 on the NSE, up +0.30% on the session. Prices on this page are indicative and for information only.
Jubilant Pharmova Ltd. has traded between ₹786.05 and ₹1,183.00 over the last 52 weeks on the NSE.
Jubilant Pharmova Ltd. has a market capitalisation of about ₹14,729 crore.
Jubilant Pharmova Ltd. trades at a P/E of 37.1, against an industry P/E of 25.9.
Open a trading and Demat account with Labdhi — it is fully digital with paperless KYC — then place a buy order for JUBLPHARMA from the Labdhi app or web platform.
Yes. You can invest in equities in a staggered manner through Labdhi. Speak to your Labdhi adviser about a plan suited to your goals and risk profile.
Who is actually trading it
Delivery against churn, the deals big enough to be reported, what the insiders did, and the benchmarks that hold Jubilant Pharmova Ltd..
Loading trading activity…
Exchange filings and end-of-day data, not a live feed. Bulk, block and insider records are published by the exchanges when a threshold is crossed, so they show reportable activity only. For information, not a recommendation to deal, and not a view on any person named above.
Disclosures. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Prices and data on this page are indicative and for information only. Nothing here is investment advice or a recommendation to buy or sell any security. Investors should consider their own objectives, financial situation and risk profile, and may wish to seek independent advice, before investing.
Figures are as reported by the company; consolidated where available. Errors and omissions excepted.
L. F. C. Securities Pvt. Ltd. · Member BSE, NSE, MCX · SEBI Stock Broker INZ000170736 · CDSL IN-DP-281-2016 · AMFI ARN-78991 · Investment Adviser (Non-Individual) INA000011617 · Compliance Officer: Mr. Santosh Patil · santoshp@labdhi.in · 022-35006933 · Investor Grievances: investorgreve@labdhi.in